72 related articles for article (PubMed ID: 33783881)
1. Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study.
Juzot C; Sibaud V; Amatore F; Mansard S; Seta V; Jeudy G; Pham-Ledard A; Benzaquen M; Peuvrel L; Le Corre Y; Lesage C; Viguier M; Baroudjian B; Dréno B; Quéreux G
J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):e511-e514. PubMed ID: 33783881
[No Abstract] [Full Text] [Related]
2. Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.
Mazumder A; Darji K; Smith K; Guo M
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593610
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Checkpoint Inhibition Associated Bullous Pemphigoid: A Propensity Matched Retrospective Cohort Study.
Sarkovics K; Kolodney JA; Kolodney MS
Br J Dermatol; 2024 Apr; ():. PubMed ID: 38644763
[No Abstract] [Full Text] [Related]
4. Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers.
Mouri A; Kaira K; Yamaguchi O; Hashimoto K; Miura Y; Shiono A; Shinomiya S; Akagami T; Imai H; Kobayashi K; Kagamu H
Front Oncol; 2021; 11():610952. PubMed ID: 33791204
[TBL] [Abstract][Full Text] [Related]
5. Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors.
Kurozumi A; Takahashi H; Watanabe T; Iwasaki Y
Thorac Cancer; 2021 May; 12(10):1625-1628. PubMed ID: 33783978
[TBL] [Abstract][Full Text] [Related]
6. Treatment-resistant bullous pemphigoid developing during therapy with immune checkpoint inhibitors.
Povilaityte E; Gellrich FF; Beissert S; Abraham S; Meier F; Günther C
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):e591-e593. PubMed ID: 33914970
[No Abstract] [Full Text] [Related]
7. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis.
Mencoboni M; Ceppi M; Bruzzone M; Taveggia P; Cavo A; Scordamaglia F; Gualco M; Filiberti RA
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808533
[TBL] [Abstract][Full Text] [Related]
9. Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER-Medicare database.
Almutairi AR; Slack M; Erstad BL; McBride A; Abraham I
Ther Adv Drug Saf; 2021; 12():2042098621991279. PubMed ID: 33796257
[TBL] [Abstract][Full Text] [Related]
10. Approval of pembrolizumab for first-line treatment of microsatellite instability-high/mismatch repair deficient colorectal cancer: estimation of incremental benefit based on restricted mean survival time.
Messori A
Eur J Gastroenterol Hepatol; 2021 May; 33(5):763. PubMed ID: 33787545
[No Abstract] [Full Text] [Related]
11. Renal allograft rejection after treatment with nivolumab in patients with metastatic renal cell carcinoma.
Ishikawa G; Sugiyama T; Ito T; Otsuka A; Miyake H
Int Cancer Conf J; 2021 Apr; 10(2):116-118. PubMed ID: 33786286
[TBL] [Abstract][Full Text] [Related]
12. Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.
Necchi A; de Jong JJ; Raggi D; Briganti A; Marandino L; Gallina A; Bandini M; Dabbas B; Davicioni E; Capitanio U; Montorsi F; Seiler R; Wright JL; Lotan Y; Black PC; Gibb EA
Eur Urol; 2021 Aug; 80(2):149-159. PubMed ID: 33785257
[TBL] [Abstract][Full Text] [Related]
13. Coexistence of bullous pemphigoid with neuropsychiatric comorbidities is associated with anti-BP230 seropositivity.
Ständer S; Hammers CM; Vorobyev A; Schmidt E; Hundt JE; Sadik CD; Lange T; Zillikens D; Ludwig RJ; Kridin K
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2067-2073. PubMed ID: 33896070
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
Wongvibulsin S; Pahalyants V; Kalinich M; Murphy W; Yu KH; Wang F; Chen ST; Reynolds K; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2022 Mar; 86(3):563-572. PubMed ID: 33819538
[TBL] [Abstract][Full Text] [Related]
15. Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors.
Gaucher L; Adda L; Séjourné A; Joachim C; Guillaume C; Poulet C; Liabeuf S; Gras-Champel V; Masmoudi K; Houessinon A; Bennis Y; Batteux B
Ther Adv Med Oncol; 2021; 13():17588359211000591. PubMed ID: 33796151
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
Front Oncol; 2021; 11():628124. PubMed ID: 33791214
[TBL] [Abstract][Full Text] [Related]
17. Complete Response of Bone Metastasis in Non-small Cell Lung Cancer With Pembrolizumab: Two Case Reports.
Asano Y; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Yonezawa H; Araki Y; Morinaga S; Kasahara K; Sone T; Tsuchiya H
Anticancer Res; 2021 Mar; 41(3):1693-1699. PubMed ID: 33788767
[TBL] [Abstract][Full Text] [Related]
18. Blood Cell Count Biomarkers Predicting Efficacy of Pembrolizumab as Second-line Therapy for Advanced Urothelial Carcinoma.
Kadono Y; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kamijima T; Seto C; Takano A; Yotsuyanagi S; Nakagawa R; Miyagi T; Aoyama S; Asahi H; Fukuda R; Mizokami A
Anticancer Res; 2021 Mar; 41(3):1599-1606. PubMed ID: 33788755
[TBL] [Abstract][Full Text] [Related]
19. The impact of lesional inflammatory cellular infiltrate on the phenotype of bullous pemphigoid.
Ständer S; Hammers CM; Vorobyev A; Schmidt E; Zillikens D; Ghorbanalipoor S; Bieber K; Ludwig RJ; Kridin K
J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):1702-1711. PubMed ID: 33896060
[TBL] [Abstract][Full Text] [Related]
20. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis.
He MK; Peng C; Zhao Y; Liang RB; Lai ZC; Kan A; Li QJ; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M
Cancer Immunol Immunother; 2021 Nov; 70(11):3207-3216. PubMed ID: 33813646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
